---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-007771"
form_type: "8-K"
ticker: null
cik: "0001178711"
company_name: "Paratek Pharmaceuticals, Inc."
filed_at: "2023-03-14T23:59:59+00:00"
generated_at: "2026-06-18T02:52:28.995671+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Paratek amends bylaws to comply with SEC universal proxy rules and DGCL updates

## Summary
- Board approved Amended and Restated Bylaws effective March 9, 2023.
- Bylaws update procedural requirements for stockholder director nominations under SEC universal proxy rules.
- Removes requirement to produce a stockholder list at meetings; adds Rule 14a-19 compliance mandate.
- Prohibits additional or substitute nominations after the deadline and requires stockholder appearance at meetings.
- Reserves white proxy cards for company use; other solicitors must use a different color.

## SEC filing metadata
- accession: 0001628280-23-007771
- form_type: 8-K
- cik: 0001178711
- company_name: Paratek Pharmaceuticals, Inc.
- filed_at: 2023-03-14T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178711/000162828023007771/0001628280-23-007771-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178711/000162828023007771/prtk-20230314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-007771
- JSON: https://secwatch.observer/filing/0001628280-23-007771.json
- Plain text: https://secwatch.observer/filing/0001628280-23-007771.txt

## Key facts
- Governance Changes
  Paratek Pharmaceuticals, Inc.: Amended and restated bylaws to update procedural requirements for director nominations and other administrative changes, effective March 9, 2023 (effective 2023-03-09).
  - Change: bylaw amendment
  - Effective: 2023-03-09
  source text: On March 9, 2023 the Board of Directors (the “Board”) of Paratek Pharmaceuticals, Inc. (the “Company”) approved the Company’s Amended and Restated Bylaws (as so amended and restated, the “Amended Bylaws”), effective as of such date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178711/000162828023007771/0001628280-23-007771-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.